Parse Biosciences launches Evercode Mouse BCR product to support antibody engineering and development for drug discovery applications

New kit can capture full-length BCR sequences from mouse samples, further enhancing its application value in immunological research

SEATTLE-Parse Biosciences, a leader in scalable single-cell sequencing solutions, today announced the expansion of its Evercode BCR ™ product line to support applications in mice. The new kit enables researchers to analyze the mouse BCR gene repertoire as well as the whole transcriptome profile of millions of cells in a single experiment, providing unparalleled scale and efficiency for antibody discovery.

The Evercode BCR platform is designed to streamline the workflow of antibody research, allowing scientists to identify individual antibody-producing cells and their associated clonal cell populations that produce specific antibodies of interest. Its unique features, such as sample fixation, enable researchers to preserve cells and samples from mice for up to six months, reducing the need for additional laboratory mice and maximizing the output of each discovery study. Additionally, the technology does not require expensive equipment and enables advanced single-cell analysis using standard laboratory tools.

Evercode BCR can comprehensively analyze the diversity of BCR clonotypes and the frequency of VDJ gene usage. At the same time, its high pairing rate with immunoglobulin heavy and light chains ensures the accuracy of antibody analysis. In addition, the platform excels at detecting rare cell populations, such as plasma cells, preserved through gentle fixation and advanced combined cell barcoding technology.

Charlie Roco, chief technology officer and co-founder of Parse Biosciences, said: “With the expansion of Evercode BCR’s capabilities to support mouse research, researchers can accelerate antibody discovery efforts by comprehensively characterizing immunological responses in disease-specific mouse models. We It is exciting to see the overall impact this technology will have in the field of immunology and antibody-based drug discovery.”

Dan Rohrer, an early adopter and Chief Technology Officer at AbTherx, expressed his appreciation for the potential of the product: “The first successful application of Evercode BCR for B cell analysis in transgenic mice is exciting. We believe that the Parse kit and technology will be able to deeply explore Atlas™ B cell lineages and perform partitioning analysis, providing superior performance in antibody discovery and diversity studies.”

Parse Biosciences will demonstrate Evercode BCR at the Antibody Engineering and Therapeutics (AET) conference in San Diego, December 15-18 . Welcome to listen to his keynote speech “Using Single Cell B Cell Sequencing Tools to Deeply Explore Antibody Libraries” to learn more details.

About Parse Biosciences

Parse Biosciences is a global biosciences company whose mission is to accelerate advances in human health and scientific research. The company empowers researchers to perform single-cell sequencing at unprecedented scale and convenience. Its pioneering methods have contributed to groundbreaking discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development and the immune system.

Based on technology developed by co-founders Alex Rosenberg and Charles Roco at the University of Washington, Parse has raised more than $100 million in funding and its products are currently used by more than 2,000 customers around the world. Its growing product portfolio includes Evercode™ Whole Transcriptome, Evercode™ TCR, Evercode™ BCR, Gene Select and data analysis solution Trailmaker™.

Parse Biosciences, located in Seattle’s vibrant South Lake Union, recently expanded and opened a new headquarters and advanced laboratory. For further details, please visit: https://www.parsebiosciences.com/ .

Disclaimer: The original version of this announcement is the officially authorized version. The translation is for convenience of understanding only. Please refer to the original text. The original version is the only legally binding version.